PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

UBC-VCH scientists use drug to repair rare birth defect

Success in mouse model is first instance of drug reversing a congenital deformity

2013-12-20
(Press-News.org) Contact information: Brian Lin
brian.lin@ubc.ca
604-822-2234
University of British Columbia
UBC-VCH scientists use drug to repair rare birth defect Success in mouse model is first instance of drug reversing a congenital deformity

University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.

They formulated the drug Ataluren into eye drops, and found that it consistently restored normal vision in mice who had aniridia (ANN-uh-ridee- uh), a condition that severely limits the vision of about 5,000 people in North America. A small clinical trial with children and teens is expected to begin next year in Vancouver, the U.S. and the U.K.

Aniridia is caused by the presence of a "nonsense mutation" – an extra "stop sign" on the gene that interrupts production of a protein crucial for eye development. Aniridia patients don't have an iris (the coloured ring around the pupil), and suffer many other eye abnormalities.

Ataluren is believed to have the power to override the extra stop sign, thus allowing the protein to be made. The UBC-VCH scientists initially thought the drug would work only in utero – giving it to a pregnant mother to prevent aniridia from ever arising in her fetus. But then they gave their specially formulated Ataluren eye drops, which they call START, to two-week-old mice with aniridia, and found that it actually reversed the damage they had been born with.

"We were amazed to see how malleable the eye is after birth," said Cheryl Gregory-Evans, associate professor of ophthalmology and visual sciences and a neurobiologist at the Vancouver Coastal Health Research Institute. "This holds promise for treating other eye conditions caused by nonsense mutations, including some types of macular degeneration. And if it reverses damage in the eye, it raises the possibility of a cure for other congenital disorders. The challenge is getting it to the right place at the right time."

A video about the study is available at http://youtu.be/L9Gx1bUxCUg.

BACKGROUND | A POTENTIAL CURE FOR ANIRIDIA

Bad vision at birth, worse vision later: Aniridia is apparent at birth because of the missing iris. Toddlers with aniridia need eyeglasses to see, sunglasses or darkened contact lenses to protect their eyes from overexposure to light, and cannot read small text. Their eyes are continually moving, making it difficult for them to focus, and have higher internal pressure (glaucoma), which damages the optic nerve as they get older. They are also prone to corneal damage in their teens and early adulthood. Eventually, most people with aniridia are considered legally blind, and must resort to Braille or expensive electronic aids to read.

The plasticity of the eye: The reversal of tissue damage in young mice, published online today by the Journal of Clinical Investigation, fits with the fact that mammals' eyes aren't fully formed at birth. Human babies don't discern colours until they are six months old, and their depth perception isn't fully developed until the age of five.

Nonsense suppressor: Ataluren, made by the New Jersey-based PTC Therapeutics, is thought to be a "nonsense suppressor" – it silences the extra "stop codon" on the gene and allows a complete protein to be assembled. The drug is currently being tested as a treatment for cystic fibrosis and Duchenne muscular dystrophy, which are also caused by nonsense mutations.

A gritty solution: Gregory-Evans' first attempt at creating Ataluren eye drops proved unsuccessful. The drug didn't dissolve, and thus irritated the mice's eyes. So she turned to Kishor Wasan, a professor and associate dean in the Faculty of Pharmaceutical Sciences, who ground the drug into a very fine powder and combined it with a solution that adhered better to the eye.

A multidisciplinary team: Gregory-Evans also collaborated with her husband, Kevin Gregory-Evans, the Julia Levy BC Leadership Chair in Macular Research and an ophthalmologist at the VCH Eye Care Centre, who treats B.C. patients with aniridia. He administered the vision tests for the mice used in the study.

Clinical trial: The forthcoming clinical trial, involving about 30 patients, will be led by Gregory-Evans in Vancouver, and is being supported by the Vision for Tomorrow Foundation, a U.S.-based charity focused on aniridia and albinism (an absence of pigmentation in skin, hair and eyes that results in poor vision). If START is proven to be safe and effective, children with aniridia would use the drops twice a day for the rest of their lives. The drug would probably not reverse the condition in adults because their eyes would already be damaged beyond repair.



INFORMATION:

Funding from a UBC alumna: Cheryl Gregory-Evans' position and this research were funded by the Sharon Stewart Testamentary Trust. Stewart, of Victoria, was born with aniridia, and at the time of her graduation from UBC in 1968, she only had five per cent of her vision. She died in 2008 and donated over $6 million to UBC for aniridia research.



ELSE PRESS RELEASES FROM THIS DATE:

Enlisting cells' protein recycling machinery to regulate plant products

2013-12-20
Enlisting cells' protein recycling machinery to regulate plant products New molecular tools for controlling production of compounds important for flavors, human health, and biofuels UPTON, NY--Scientists at the U.S. Department of Energy's Brookhaven ...

New mechanism that permits selective capture of microRNAs in nanovesicles that shuttle between cells

2013-12-20
New mechanism that permits selective capture of microRNAs in nanovesicles that shuttle between cells The study presents the first description of a set of related nuceleotide sequences essential for the role of these small molecules in ...

More mentions in the FT linked to greater popularity of stocks

2013-12-20
More mentions in the FT linked to greater popularity of stocks A 6-year study of the Financial Times has found that the more frequently a company is mentioned in the newspaper in the morning, the greater the volume of shares traded in that company during the ...

Efforts to curb climate change require greater emphasis on livestock

2013-12-20
Efforts to curb climate change require greater emphasis on livestock CORVALLIS, Ore. – While climate change negotiators struggle to agree on ways to reduce carbon dioxide (CO2) emissions, they have paid inadequate attention to other greenhouse gases associated ...

Birth of black hole kills the radio star

2013-12-20
Birth of black hole kills the radio star Research clears telescope, disproves long-held theory Astronomers led by a Curtin University researcher have discovered a new population of exploding stars that "switch off" their radio transmissions before collapsing ...

An earthquake or a snow avalanche has its own shape

2013-12-20
An earthquake or a snow avalanche has its own shape However, it is crucial what one observes – paper fracture or the avalanching of snow. The results were just published in the Nature Communications journal. Avalanches of snow or earthquakes can be described in other ...

Smooth or grainy?

2013-12-20
Smooth or grainy? A SISSA paper reviews research on the grain of space-time Smooth" or grainy? Is space-time continuous or is it made up of very fine (10-35 metres on the "Planck scale") but discrete grains, if we look at it very ...

IRB develops ChroGPS, a new generation visual browser of the epigenome

2013-12-20
IRB develops ChroGPS, a new generation visual browser of the epigenome This is a software application that provides easily interpretable maps from which to analyse and understand the immense volume of epigenetic and genetic ...

Birth control at the zoo

2013-12-20
Birth control at the zoo Vets meet the elusive goal of hippo castration Common hippopotami (Hippopotamus amphibius) are vulnerable to extinction in the wild, but reproduce extremely well under captive breeding conditions. Females ...

Breaking down cancer's defense mechanisms

2013-12-20
Breaking down cancer's defense mechanisms A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers. The method uses a drug which breaks down the ...

LAST 30 PRESS RELEASES:

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

[Press-News.org] UBC-VCH scientists use drug to repair rare birth defect
Success in mouse model is first instance of drug reversing a congenital deformity